Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | HTR2B | P41595 | 3/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | PRCP | P42785 | 4/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163850 | 0.80 | HTR2C (0.57) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL18766048 | 0.80 | HTR2C (0.57) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL162669 | 0.80 | HTR2C (0.57) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL175085 | 0.80 | HTR2C (0.63) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL9635463 | 0.79 | HTR6 (0.46) | HTR2CHTR2AHTR2B | |
| Iodide SCHEMBL162026 | 0.79 | HTR2C (0.56) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| Bromide SCHEMBL161200 | 0.79 | HTR2C (0.56) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL1961198 | 0.77 | HTR2C (0.58) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL4540545 | 0.74 | HTR2C (0.54) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| Phosphoric Acid SCHEMBL166016 | 0.73 | HTR2C (0.49) | HTR2CHTR2AHTR2BTAAR1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | HRH3, HRH4, HRH1 | HTR2C 13/4885HTR2A 19/4885HTR2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.